Register today and get 15% OFF on your FIRST ORDER

WHY C'BELLA

Our Mission Statement

Our mission is to provide healing and wellness to the world, by developing the highest quality, nature-derived products, using the best available science and technology.

What Does Quality Mean at c'bella?

Purest Ingredients

We use the purest, plant-derived ingredients available to develop proprietary formulations with a proven shelf-life.

Honest Results

All of our products are engineered in a DEA approved facility, using the best available technology and equipment.

Quality Guaranteed

We undergo extensive testing using FDA approved tests and protocols to establish optimal bioavailability, penetration, retention, stability, and shelf life.

Our Promise

To Provide The Most Potent Products

Potency has two components: the concentration of CBD in the bottle and the absorption by the body. We pack the highest concentrations of CBD into highly absorbable formulations, while adhering to safe, recommended limits.

To Provide The Highest Quality

We follow state of the art, pharmaceutical “Quality By Design” principles, so that our products are consistently the highest quality available.

To Provide The Longest Product Shelf-Life

We test our products extensively to make sure they are compliant with FDA guidelines & regulations regarding expiration dates. Our products retain at least 90% or more of the labeled CBD amount after 12 months. Our Nano CBD products stay nano for at least one year, maintaining their original potency, stability, and absorption.

Our Medical Advisory Board

Juan Sanchez-Ramos, MD, PhD

Dr. Sanchez-Ramos is a Professor of Neurology at the University of South Florida in Tampa where he holds the Helen Ellis Endowed Chair for Parkinson’s Disease Research and is Director of the HDSA Center of Excellence for Huntington’s Disease. He is also the Medical Director of the non-profit Parkinson Research Foundation based in Sarasota FL. In addition to teaching and attending to patients with Movement Disorders, he has directed basic research projects in neurodegeneration, neurotoxicology, and adult stem cell biology. Dr. Sanchez-Ramos is actively engaged in studying the role of the endocannabinoid system in brain repair following traumatic brain injury. Dr. Sanchez-Ramos, in collaboration with SGN Nanopharma, has an actively funded research program from the State of Florida (Florida I4 HiTech Grant) entitled “Nanoformulations of Cannabinoids for Nose to Brain Delivery.” He has over 200 publications in peer-reviewed journals.


Dr. Sanchez-Ramos received a Ph.D. in Pharmacology and Physiology from the University of Chicago and a medical degree (M.D.) from the University of Illinois. He trained in Neurology at the University of Chicago and as a Fellow in Movement Disorders at the University of Miami.

Dr. Leonard Miller, MD

Dr. Miller is a leading plastic surgeon in Boston who serves on the faculty staff of the Harvard Medical School with full operating privileges at Beth Israel Deaconess Hospital, New England Baptist Hospital (Chief of Plastic Surgery), and the Massachusetts Eye and Ear Infirmary. He is actively involved in the development of new skincare technologies and cosmetic products.

Dr. Stephen Warren, MD

Dr. Warren is a well-known plastic and Craniofacial surgeon and the Vice-Chairman of Plastic Surgery, New York University Medical Center. Dr. Warren is on the editorial Board of several International Medical Journals and has over 200 publications. Dr. Warren has diverse interests including tissue engineering, outcomes research, and regenerative medicine. 

Our Team

Navdeep Jaikaria, Ph.D.; Founder, Chairman, CEO

Dr. Jaikaria has been at the forefront of cutting-edge biotechnologies in his various professional roles and has trained at some of the finest institutions in India and the US with leading scientists of his time.  He founded SGN Nanopharma Inc. and its Indian subsidiary, New India Biopharma Pvt. Ltd., in 2010 and c’bella naturals in 2019. Before founding SGN, Dr. Jaikaria was a consistently top ranked Biotechnology Equity Research Analyst on Wall Street and won several distinctions including one of the five best stock-pickers in Biotechnology in the Wall Street Journal’s annual “Best on the Street” Analysts survey in 2007. His investment opinions were widely cited in print and broadcast media including The Wall Street Journal, Financial Times, Businessweek, Forbes, CNNfn, CNBC and CNN.  Dr. Jaikaria obtained his B.Sc. from All India Institute for Medical Sciences, New Delhi in Human Biology (Rank II), Ph.D. at the New York Medical College and post-doctoral fellowship at The Rockefeller University, New York.

Sanjeev Srivastava, MBA; Chief Financial Officer

Sanjeev has an MBA in Finance from NYU (Stern School) and a B.S. in Chemical Engineering from University of Rochester. He brings strong strategic, analytic, management and finance skills to SGN. He has a diverse and rich Cross-Border experience in Executive Leadership including as General Manager, CFO, Wall Street including Portfolio management and currently sits on Non-for-Profit Boards.

Vineet Singhal, BE, MBA; Chief Operating Officer

Accomplished business leader with over 20 years of experience in Specialty Pharmaceuticals and Consumer Healthcare. He was formerly Country Head of Shire/Baxalta/Takeda in India and Novartis Consumer Health in South East Asia. He delivered strong and sustainable growth in businesses through organic levers like new product launches and deeper market access and inorganic levers such as M&A and Licensing-in opportunities. He develops an aspirational and shared plan with a strong leadership team, making bold choices, pre-empting risks, and follows through with a focus on execution. He has proven experience in operationalizing robust governance processes needed to execute growth opportunities, manage transitions and address risks & challenges. He is known to build a culture of resilience through positive leadership, generative conversations, and a habit of cross-functional collaboration. He brings a unique mix of global roles such as Strategic Planning & Business Development, and Country Leadership across the USA, Europe, South East Asia, and India. He has a Bachelor in Mechanical Engineering from Delhi University and an MBA from Cranfield School of Management in the UK.

As the Chief Operating Officer at SGN, he is part of the leadership team transforming the company to deliver on an explosive growth agenda. Vineet has implemented processes and operating systems that bring the Leadership Team together on a common platform with clear roles and accountabilities while building a strong operating rhythm to monitor day-to-day execution. He has been instrumental in creating an aggressive business development pipeline with deal closures and helped initiate various Clinical trials and build out a robust regulatory & supply chain backbone for the company.

Pranav Patel, Ph.D.; Vice President, R&D

Dr. Pranav Patel is Vice President, R&D at SGN Nanopharma. He has over 23 years of pharmaceutical nous and generic drug research and development experience in the US and India and has more than 22 peer-reviewed publications and patents. Additionally, he has extensive experience developing “controlled drugs” under DEA approvals and as a DEA liaison. At SGN, he has been instrumental in creating the robust MNP Platform-based pipeline and developing many Cannabinoid based products to treat numerous conditions. Before SGN, Dr. Patel was previously Chief Scientific Officer at Aurex Laboratories, where he helped develop the generic versions of many soft gelatin capsules. Before that, he was the Director of R&D At Navinta LLC, where he helped develop and commercialize many generic drugs for US FDA approval and ANDA/DMF filings. 

Dr. Patel obtained his Ph.D. in Medicinal Chemistry from the Florida Institute of Technology. During his doctoral and post-doc research under Dr. Joshua Rokach (world-renowned for pioneering the synthesis of several inflammatory mediators and drugs, including the blockbuster asthma drug Singulair), Dr. Patel was extensively involved in prostaglandin and isoprostane research geared towards new drug development for the treatment of many chronic diseases like Asthma, Alzheimer’s, atherosclerosis and cancer. He is currently working on a nose-to-brain drug delivery system with Dr. Sanchez-Ramos (Neurology, USF). Additionally, he is developing treatments for traumatic brain injury in collaboration with Dr. Shyam Mohapatra (Pharmacy, USF).